FDA's 1st Chief Scientist speaks

Written byBob Grant

| 2 min read

Last week, the US Food and Drug Administration linkurl:named;https://www.fda.gov/bbs/topics/NEWS/2008/NEW01816.html cancer biologist linkurl:Frank Torti;https://www1.wfubmc.edu/canbio/Faculty/Torti+F.htm as the agency's first ever Chief Scientist. Torti, who is also the director of Wake Forest's linkurl:Comprehensive Cancer Center,;https://www1.wfubmc.edu/cancer/ will leave North Carolina and begin work early next month at the FDA. The researcher and clinician took time to talk with me and share his plans on building up the science side of the agency's mission. Torti, who will report directly to FDA commissioner linkurl:Andrew C. von Eschenbach;https://www.the-scientist.com/article/display/12978/ and oversee the FDA's linkurl:National Center for Toxicological Research,;https://www.fda.gov/NCTR/ said he hopes "not to remediate, but to augment" science at the FDA. "We intend to have a substantial impact across the board by not only developing new scientific insights through collaborations with academia, industry where appropriate, and others, as well as developing them within the FDA," Torti said, "but just pushing that science forward across the different centers of the FDA, creating levels of integration that weren't there before. And through all these mechanisms, make the FDA as scientifically contemporary and relevant as it should be." One major step, Torti said, will be to recruit young talent into the agency's ranks with the help of a new FDA fellowship program that aims to attract 2,000 young scientists and clinicians. "I am particularly very interested in increasing the training efforts in regulatory science at the FDA," he said. "We want to go out and recruit the very best young scientists." Specific areas where having a head scientist could speed approvals of safe, effective drugs include emerging treatments involving cancer stem cells, nanotechnology, and post-marketing surveillance of the safety and efficacy of drugs, Torti said. When I asked Torti how he might ensure timely review of new drug applications, a process which has recently been slowed by backlogs, he returned to his goal of recruiting fresh faces into the agency. "I think speeding up regulatory processes that are quite advanced will come from the recruitment of a very specific kind of person who understands and can deal with those late-stage regulatory issues," he said. Torti said, however, that he has no delusions as to his immediate impact at the FDA. "I don't think my job is going to move ten drugs that needed someone to review the paperwork more quickly," he said. "But on the other hand, I do think that over time my role will really help that process." To listen to a brief snippet of my conversation with Frank Torti, click linkurl:here.;https://images.the-scientist.com/supplementary/audio/torti_cut.wav And please share your thoughts about the FDA's new chief scientist position and what impact you think it'll have on the agency by posting a comment linkurl:here.;https://www.the-scientist.com/forum/addcomment/54555/ (__Editor's Note: An earlier version of this story incorrectly stated that Torti would be overseeing the NIH's National Toxicology Program. In fact, he will be overseeing the FDA's National Center for Toxicological Research. __The Scientist__ regrets the error.__)

Meet the Author

Bob Grant

From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

View Full Profile

FDA's 1st Chief Scientist speaks

The Scientist ARCHIVES

Become a Member of

Meet the Author

Bob Grant

Related Research Resources

Epic Fail: Sea-Monkeys Sabotage Fieldwork

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Improving rAAV Production for Viral Vector Manufacturing

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

What Dictates PCR Success Before Amplification Begins?

Overcoming Immunotherapy Resistance in Liver Cancer

Products

Product News

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates